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Abstract
Background: In areas where non-falciparum malaria is common rapid diagnostic tests (RDTs)
capable of distinguishing malaria species reliably are needed. Such tests are often based on the
detection of parasite lactate dehydrogenase (pLDH).
Methods: In Dawei, southern Myanmar, three pLDH based RDTs (CareStart™ Malaria pLDH
(Pan), CareStart™ Malaria pLDH (Pan, Pf) and OptiMAL-IT®)were evaluated in patients presenting
with clinically suspected malaria. Each RDT was read independently by two readers. A subset of
patients with microscopically confirmed malaria had their RDTs repeated on days 2, 7 and then
weekly until negative. At the end of the study, samples of study batches were sent for heat stability
testing.
Results: Between August and November 2007, 1004 patients aged between 1 and 93 years were
enrolled in the study. Slide microscopy (the reference standard) diagnosed 213 Plasmodium vivax
(Pv) monoinfections, 98 Plasmodium falciparum (Pf) mono-infections and no malaria in 650 cases.
The sensitivities (sens) and specificities (spec), of the RDTs for the detection of malaria were-
CareStart Malaria™ pLDH (Pan) test: sens 89.1% [CI95 84.2-92.6], spec 97.6% [CI95 96.5-98.4]
OptiMal-IT®: Pf+/- other species detection: sens 95.2% [CI95 87.5-98.2], spec 94.7% [CI95 93.3-95.8];
non-Pf detection alone: sens 89.6% [CI95 83.6-93.6], spec 96.5% [CI95 94.8-97.7]
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CareStart Malaria™ pLDH (Pan, Pf): Pf+/- other species: sens 93.5% [CI9585.4-97.3], spec 97.4%
[95.9-98.3]; non-Pf: sens 78.5% [CI9571.1-84.4], spec 97.8% [CI95 96.3-98.7]
Inter-observer agreement was excellent for all tests (kappa > 0.9). The median time for the RDTs
to become negative was two days for the CareStart™ Malaria tests and seven days for OptiMAL-
IT®. Tests were heat stable up to 90 days except for OptiMAL-IT® (Pf specific pLDH stable to day
20 at 35°C).
Conclusion: None of the pLDH-based RDTs evaluated was able to detect non-falciparum malaria
with high sensitivity, particularly at low parasitaemias. OptiMAL-IT® performed best overall and
would perform best in an area of high malaria prevalence among screened fever cases. However,
heat stability was unacceptable and the number of steps to perform this test is a significant
drawback in the field. A reliable, heat-stable, highly sensitive RDT, capable of diagnosing all
Plasmodium species has yet to be identified.
Background
Malaria is one of the few diseases for which it is quick and
simple to make an accurate biological diagnosis, even in a
low-technology setting. Despite this clinical diagnosis is
practised widely, even though it has been shown repeat-
edly to be unreliable [1,2]. In a cross-over study in Zanzi-
bar of 1,887 patients, use of RDTs altered prescribing
patterns of antimalarials and anti-bacterials and resulted
in improved patient management without increasing
costs [3]. Availability of biological diagnosis does not nec-
essarily prevent over-treatment from occurring. In some
areas, patients are still likely to receive an antimalarial
treatment in the presence of a negative slide or RDT result
[4,5].
The choice of diagnostic method in most of the malaria-
affected world will be between microscopy and a rapid
diagnostic test. Maintaining a high standard of micros-
copy is challenging and depends on having well-trained
experienced technicians, who are not overburdened with
slides to read, a continuous supply of good quality stain-
ing reagents and appropriately maintained microscopes.
RDTs for malaria are based on the detection of either his-
tidine-rich protein 2 (HRP-2), produced only by Plasmo-
dium falciparum, parasite specific lactate dehydrogenase
(pLDH) produced by all four species or plasmodium
aldolase from the parasite glycolytic pathway, also found
in all species. HRP-2 based tests may be misleading in
areas of high transmission because they remain positive
for a number of days or weeks after an infection, even if
treated, thus a positive result with a history of a recently
treated infection is difficult to interpret. Another limita-
tion of HRP-2 based tests is their geographically variable
sensitivity, attributed to polymorphisms in HRP-2 [6].
Tests based on detection of pLDH or aldolase allow para-
site speciation, do not appear to show geographical varia-
bility in their ability to detect malaria and revert to
negative more quickly than HRP2 based tests, although
production of pLDH from gametocytes after elimination
of asexual stages means some will stay positive for a
number of days [7]. However, to date the sensitivity of
these tests under field conditions has been reported fre-
quently as falling below 90% [8,9]. There are concerns
about the stability of all types of tests if transportation and
storage conditions are not controlled, but pLDH tests
appear to be particularly vulnerable [10].
In areas where mixed species infections are common e.g.
Asia, Latin America, a reliable test to distinguish between
species is needed, since the treatments recommended for
falciparum and non-falciparum infections are different. In
most parts of the world non-falciparum infections remain
susceptible to chloroquine, although chloroquine-resist-
ant vivax malaria has emerged in parts of Indonesia and
South America [11,12].
To be adopted in the field a test needs to be >95% sensi-
tive and specific for the detection of falciparum malaria at
a parasitaemia ≥ 100/μl. High sensitivity and specificity
for the diagnosis of non-falciparum malaria are desirable;
however there is no internationally agreed threshold.
Criteria used to select the tests under evaluation in this 
study
The CareStart™ Malaria pLDH (Pan) test, a two-line test,
shown to be reliable for the diagnosis of falciparum
malaria was selected to validate its use in an area where
non-falciparum infections were prevalent [13]. The WHO
does not endorse particular tests but lists products availa-
ble for procurement, which meet certain criteria e.g. man-
ufactured to good manufacturing practice standards [14].
Since the time this study was performed, in order to be
included in the procurement list, products must now also
have been volunteered for the WHO product testing pro-
gramme. The CareStart™ Malaria pLDH (Pf, Pan) three-
line test was included in this study in the hope that the
good performance of the two-line test might be repro-Malaria Journal 2009, 8:241 http://www.malariajournal.com/content/8/1/241
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duced with this test, and OptiMAL-IT® was also included,
since published results suggested it was one of the most
sensitive RDTs for diagnosing non-falciparum species
[15].
Aims
The main aims of the study were to evaluate the sensitiv-
ity, specificity, positive and negative predictive values of
the three RDTs for the detection of vivax and falciparum
malaria compared to microscopy of Giemsa-stained
blood slides, to study the time taken for positive tests to
become negative, and to evaluate the inter-observer agree-
ment, ease of use of the tests and heat stability.
Subsidiary aims included investigating differences in sen-
sitivity of the tests in the under five year age group and the
effect of parasitaemia or other covariates on sensitivity. In
addition, sensitive PCR species detection was evaluated as
an alternative reference standard in a subset of patients,
which included all patients with positive slides, all
patients with false positive RDT results compared to
microscopy, and 20% of patients with negative slides
selected at random.
Study site and population
The study took place in a clinic where the non-govern-
mental medical Organisation MSF-Switzerland works
with the agreement of the Ministry of Health in Sonsin-
phya, Thayetchaung Township, Dawei in the south of
Myanmar. The four Plasmodium species (falciparum,
vivax, ovale and malariae), which commonly affect
humans, are found here where malaria has a seasonal inci-
dence, with a peak in the rainy season between June and
August. The vast majority of cases (>80%) occur in
patients over 5 years old.
Ethical review
The study protocol was approved by the Comité de Protec-
tion des Personnes (CPP), Ile-de-France XI, St- Germain-
en-Laye, France and local authorities in Myanmar gave
their permission for the study to be implemented.
Study design
A prospective, single-blind evaluation of three RDTs com-
pared to slide microscopy.
Sample size
Based on local 2006 data, when prevalences of Pf and Pv
among fever cases were 30% and 10% respectively, it was
estimated that 460 patients would be required to detect Pf
with sensitivity and specificity of 90% (alpha error 0.05,
precision 5%) and 960 patients would be required to
detect Pv with the same sensitivity and specificity but a
precision of 6% (N = 1383 with precision 5%).
The sample size was set at 1,000. The study was not pow-
ered to evaluate detection of mixed infections. A conven-
ient sample size of 120 patients with a positive RDT result
and positive malaria slide (60 Pf, 60 Pv) was chosen to
describe the time taken for the RDTs to become negative.
Informed consent
Patients were provided with an information sheet and the
study was explained in their own language by the study
personnel (Burmese or Karen). Written consent was
obtained from participants or parent/guardian in the case
of children.
Inclusion and exclusion criteria
Main inclusion criteria were age> two years, with sus-
pected malaria defined as fever (tympanic tempera-
ture>37.5°C), or a history of fever in the previous 48
hours, no signs of severity/danger signs. Exclusion criteria
were pregnancy or having received a treatment course of
antimalarials in the previous 4 weeks. To be eligible for
inclusion into the follow-up study subjects needed to
have a positive malaria slide for Pf or Pv mono-infection
in conjunction with a positive RDT and to be able to
attend follow-up until 28 days.
Rapid diagnostic tests evaluated
CareStart™ Malaria pLDH (Pan) (AccessBio, New Jersey,
US). A two-line test.
CareStart™ Malaria pLDH (Pan, Pf) (AccessBio, New Jer-
sey, US). A three-line test.
OptiMAL-IT® pLDH (Pan, Pf) (Diamed AG Switzerland).
A three-line test.
The terms 'two-line' and 'three- line' are used to facilitate
distinction between the two types of CareStart™ Malaria
tests evaluated. The result of the CareStart™ Malaria two-
line pLDH (Pan) was recorded as negative, positive or
invalid. The CareStart™ Malaria three-line pLDH (Pan, Pf)
and OptiMAL-IT® test results were recorded as negative, Pf
(+/- P.other), non-Pf or invalid. It should be noted that
interpretation of the CareStart™ Malaria pLDH (Pan, Pf)
test differs from OptiMAL-IT® in that a test with a positive
control line, positive Pf pLDH band and negative pLDH
(Pan) should be interpreted as Pf. For OptiMAL-IT® both
Pf and pan pLDH bands must be positive to interpret the
test as Pf.
Blinding
Tests were labelled with the patient code on the under-
side. Two laboratory technicians performed the tests, took
the capillary blood sample for haematocrit, the sample
onto filter paper for PCR analysis and prepared the
malaria blood slide. The slide was passed to another lab-Malaria Journal 2009, 8:241 http://www.malariajournal.com/content/8/1/241
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oratory technician to stain and read, who was unaware of
the RDT results. One test was handed to each of three
readers for interpretation at the appropriate time. The tests
were then handed on to three different readers, who were
unaware of the first interpretation, to read and interpret
the tests 10 minutes later. For the duration of the study
each of the six readers read the same type of test and made
the same reading each time (i.e. first or second).
Visit schedule
All patients were seen on day 0 and the first 120 patients
who agreed (60 with slide confirmed Pf mono-infection,
60 with Pv) were asked to return on days 2, 7, 14, 21 and
28 to document when the tests became negative. A
malaria slide was performed simultaneously. Once the
test was negative on any follow-up day they did not need
to return for subsequent visits.
Laboratory procedures
RDTs were performed according to the manufacturers'
instructions. For all tests, a test without a control line was
considered invalid and repeated. The number of invalid
tests was recorded. Blood films were stained with 10%
Giemsa for 20 minutes and read by experienced techni-
cians. Parasite stages were counted separately by species.
Trophozoites were counted on the thick (if count <500/
500 WBC) or on the thin smear. At least 200 high power
fields were examined before a slide was declared negative.
PCR species sensitive detection
Sensitive species PCR genotyping on blood samples on fil-
ter paper was performed by the Shoklo Malaria Research
Unit (SMRU) blind to the RDT and microscopy results.
Parasite DNA was extracted from the bloodspot using the
saponin lysis/chelex extraction method developed by
Wooden and colleagues in 1993 [16]. DNA was stored at
-20°C until processed. The targets of the Plasmodium-spe-
cies PCR amplification are the genes coding for the small
subunit ribosomal RNA (ssRNA). In the first amplification
reaction (Nest 1), genus-specific primers were used to
amplify a fragment of the ssrRNA genes of any Plasmodium
parasite. The product of the first reaction was then used as
the DNA template for a second amplification reaction
(Nest 2). Species-specific primer pairs in the Nest 2 round
amplified the specific sequence for P. falciparum, P. vivax,
P. malariae or P. ovale. Primers and amplification condi-
tions were those described by Snounou et al [17].
Treatment
Patients with vivax malaria were treated with chloroquine
25 mg/kg divided over three days (10+10+5). Patients
with falciparum malaria or mixed falciparum/vivax infec-
tions with a falciparum parasitaemia of < 4% infected red
blood cells (irbc) were treated with mefloquine (25 mg/
kg) + artesunate (4 mg/kg/day for three days)(MAS3). If
the falciparum parasitaemia was ≥ 4 %  i r b c  t h e y  w e r e
treated with a seven-day regimen of artesunate (4 mg/kg
for one day followed by 2 mg/kg/day for six days) and
mefloquine (25 mg/kg) (MAS7). Those patients asked to
come back for repeat testing to evaluate when the tests
became negative had all doses of treatment supervised.
Assessment of ease of use of tests
Ease of use of the tests was assessed using qualitative and
quantitative criteria-Qualitative- laboratory technicians
performing the tests were asked to rank the tests in order
of preference where 1 corresponded to their most pre-
ferred test and 3 to their least preferred in each of the fol-
lowing categories - ease of taking blood, ease of adding
reagents, ease of interpretation and overall performance.
Quantitative - number of steps in the procedure, time to
wait before reading test.
Quality assurance and quality control
The laboratory was already implementing internal quality
control (QC) checks monthly and slides were sent period-
ically to an external laboratory (SMRU). In this study all
slides were double-read, blind, by experienced techni-
cians, with approximately seven days between the first
and second readings. Slides with discordant results
between two microscopists, defined as positive/negative
discordance for asexual stages; species discordance for
asexual stages; asexual parasite density discordance (dif-
ference in parasitaemia ≥ 50%) and gametocyte or malaria
pigment reporting discordance were sent to SMRU for a
third blind reading. The third reading was taken as the
definitive result.
A sample of 120 of each of the CareStart Malaria™ tests
(one box contains 60 tests) and 96 OptiMAL-IT® tests (one
box contains 24 tests) were sent to the Malaria RDT Qual-
ity Assurance Laboratory, Research Institute for Tropical
Medicine, Muntinlupa City, Manila, Philippines for heat
stability testing and quality control of performance
according to Standard Operating Procedures (SOPs)
under development by the WHO, Research Institute for
Tropical Medicine, and others as part of a joint initiative
to develop laboratory methods for malaria RDT assess-
ment. Stability of the test result at one week in the field
was also evaluated with a third blind reading made one
week after the first to see whether retrospective checking
of RDTs could be introduced as part of a regular QC pro-
cedure.
Data management and analysis
Data from the case report forms was checked and entered
on site in Microsoft® Access. The source data forms with
the RDT results were entered separately into Microsoft®
Excel. The two databases of RDT results were cross-Malaria Journal 2009, 8:241 http://www.malariajournal.com/content/8/1/241
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checked. All discrepancies were corrected by returning to
the source documents. Statistical analyses were performed
using SPSS® version 14.0 (Chicago, USA). Sensitivity, spe-
cificity, positive and negative predictive values of each test
were calculated using microscopy as the reference stand-
ard. Sensitivity of the RDTs for detection of Pf and Pv
mono-infections were then calculated. The first reading
made of the RDT was used for these calculations. Sub-
group analyses were performed to calculate the sensitivity
and specificity of the tests at a parasitaemia below 100/μL
and in the under five years age group. Multivariate analy-
sis (logistic regression) was used to explore the relation-
ship of selected covariates on test sensitivity and
specificity (age, haematocrit, parasitaemia). Sensitivity
and specificity of the tests and of slide microscopy com-
pared to species PCR genotyping were also evaluated in a
subset of patients. The confidence intervals (Wilson
method) were calculated using Confidence Interval Anal-
ysis (CIA) software, version 21.2 (©Trevor Bryant 2002-
2004, University of Southampton, UK). Agreement
between the first and second and first and third readings
of each RDT was assessed using the kappa coefficient.
Definitions
Slides for which only gametocytes were detected were con-
sidered in two different ways, firstly as positive for that
species, since gametocytes are known to produce pLDH,
and secondly as negative since missing a solitary gameto-
cytaemia is not usually an indication for treatment. Slides
reported as showing malaria pigment only by microscopy
were considered as negative.
Results
Between 30th  August and 9th  November 2007, 1,004
patients were enrolled in the study out of a total of 1,833
patients attending the clinic with fever (Figure 1). The tar-
get sample size was exceeded in order to include 100
patients with falciparum malaria into the study. Reasons
for non-inclusion of screened patients were not docu-
mented. Baseline characteristics of the included popula-
tion are shown in Table 1. No serious adverse events were
detected during the study. There were 13 protocol viola-
tions. One subject was less than two years of age, the lower
limit for inclusion into the study. Eight patients with a
parasitaemia ≥ PFT 40/1,000 irbc were treated with MAS3
instead of MAS7. Four patients were recruited into the fol-
low-up phase of the study on the basis of a positive
malaria smear result when their RDT result was negative
and had to be excluded from the analysis.
Malaria slide results
The results of the slide microscopy on the day of enrol-
ment (adjusted after quality control) are shown in Table
2. The sensitivity, specificity, positive and negative predic-
tive values of the RDTs compared to slide microscopy are
shown in Tables 3 and 4.
Effect of parasitaemia and age on sensitivity and 
specificity of RDTs
Sensitivities of the RDTs for detection of malaria at higher
and lower parasitaemia were compared using 100 para-
sites/μL as the cut-off (Table 5). There were 113 P. falci-
parum and 218 P. vivax monoinfections recorded over the
period of follow up with a geometric mean [range] parasi-
taemia of 4,688 [16-346,737]/μL and 1,733 [16-
107,152]/μL respectively.
The median [range] parasitaemias associated with a false
negative RDT result were Pf 16/μL [16,16] (n = 5), Pv 16/
μL [16-128] (n = 20) for CareStart™ Malaria two-line
Table 1: Baseline characteristics of included population
Male N (%) 517 (51.5)
Age in years 13 [1-93]
Weight in kg 30 [7-82]
Onset of symptoms in days 3 [1-20]
History of fever N (%) 1003 (99.9)
Temperature°C 37.2 [34.6-41.0]
Temp ≥ 37.5°C N (%) 420 (41.8)
Previous antimalarials N (%) 3 (0.3)
Haematocrit % 38(11-57)
Results expressed as median [range], unless otherwise stated
Patient flow diagram Figure 1
Patient flow diagram. Note: 'Other 'includes mixed infec-
tions and slides with either malaria pigment or gametocytes 
only. One subject <2 years enrolled (protocol violation).
58
followed until
negative
P.falciparum
98
58
followed until
negative
P.vivax
213
Other
43
Negative
650
1004 patients
ENROLLED
Median age 13 (1-93)
1833 patients
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pLDH (Pan); Pf 16/μL [16,16] (n = 5), Pv 24/μL [16-288]
(n = 30) for CareStart™ Malaria three-line pLDH (Pan, Pf)
and Pf 16/μL [16-576] (n = 5), Pv 24/μL [16-48 230] (n =
14) for OptiMAL-IT®.
None of the patients with a presenting parasitaemia meet-
ing the local definition of hyperparasitaemia (PFT ≥ 4%
irbc) had a false negative RDT result. The number of
patients under five years of age with positive slide results
were small. Test sensitivities are shown in Table 6. In a
multivariate analysis only the association between parasi-
taemia and RDT result was significant.
Inter-observer agreement
Results for inter-observer agreement between the first and
second readings of the tests performed 10 minutes apart
and the first and third readings of the tests, performed one
week apart are shown in Table 7.
Time for tests to become negative
Of 116 patients evaluated the median [range] time in days
for the tests to become negative was 2 [2-14] for Pf
monoinfections using both CareStart™ Malaria tests and 7
[0-21] for OptiMAL-IT® and for Pv monoinfections was 2
[2-7] for CareStart™ Malaria 2 line pLDH (Pan), 2 [2-14]
for CareStart™ Malaria three line pLDH (Pan, Pf) and 7 [0-
14] for OptiMAL-IT®.
Results of ease of use evaluation
General remarks made were that the Pf band of the Care-
Start™ Malaria three-line pLDH (Pan, Pf) test could be
very faint making reading more difficult. For some tests
the background was completely red, invalidating the test.
It was important not to delay before adding the buffer
since the tests could dry out quickly and give an invalid
result. The information provided with the CareStart™
Malaria tests was unclear, the title of the packet inserts for
both tests was the same and the two tests were in identical
packaging, causing confusion. The pipettes for the Care-
Start™ Malaria tests were provided separately, unlike Opti-
MAL-IT® where each test is pre-packed with the lancet,
pipettes, alcohol swab and instructions. The buffers for
the two tests were unlabelled. These points gave rise to a
perception that the tests were of inferior quality to the
Table 2: Result of malaria slide microscopy for admission slides and all slides
Final microscopy result DAY 0
N (%)
ALL SLIDES
N (%)
Negative 650 (64.7) 906(68.7)
PF trophozoites 98 (9.8) 113(8.6)
Parasitaemia/μL, geometric mean [range] 9618
[16-346737]
4688
[16-346737]
PV trophozoites 213 (21.2) 221(16.8)
Parasitaemia/μL, geometric mean [range] 2018
[16-107152]
1733
[16-107152]
PFT+PVT 6 (0.6) 7(0.5)
PMT 21(2.1) 21(1.6)
POT 7(0.7) 7(0.5)
Malaria Pigment 1(0.1) 17(1.3)
PF Gametocytes 2(0.2) 13(1.0)
PV Gametocytes 0 7(0.5)
Other1 6(0.6) 6(0.5)
1 Other:
PVT, PVG, PFG 1/500 WBC
PFT 45/1000 RBC; PVG 2/500; MP
PFT 294, PFS 3/500 WBC, PMT 5, PMS 5, PMG 2/500 WBC, PVT 5, PVG 1/500 WBC
PVT 1, PVG 12, PVS 1/500 WBC, PMT 1, PMG 4/500 WBC
PFT 11, PMT 3, PMG 1, PVT 33, PVG 2/500 WBC, Very Rare MP
PFT 27/1000 RBC, PMT 50/500, PMG 70/500, PMS 8/500, MP
PF P.falciparum; PV P.vivax; PM P malariae; PO P.ovale; T = trophozoitesMalaria Journal 2009, 8:241 http://www.malariajournal.com/content/8/1/241
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OptiMAL-IT®. When it was very windy there were more
invalid OptiMAL-IT® tests because they tended to dry out
between steps. The OptiMAL-IT® pipette was found to be
more difficult to use requiring twice as much blood as the
CareStart™ Malaria tests. It was thought to be the most
complicated test to perform, with 10 steps compared to
only four for the CareStart™ Malaria tests. The CareStart™
tests were ranked joint first as the easiest to use.
Quality assurance/Quality control results
Slide microscopy
From a total of 1,318 slides read, 228 (17%) were sent for
a third blind reading. Of these 76 (5.7%) were sent
because of differences in species between the first and sec-
ond readers, 118 (9%) because of >50% variation in par-
asitaemia between first and second readings and the
remainder because of discrepancies in recording of game-
tocytes or malaria pigment.
Rapid diagnostic test handling and quality control results
In July 2007, tests were sent from the manufacturers to the
MSF logistic department in France by air and then onto
Yangon. After one week in customs they were stored in a
container at 20°C for two weeks. They were then trans-
ported to the central laboratory in Dawei, where the tem-
perature varied between 12 and 24°C, and humidity from
62-81% (based on twice daily recordings). Tests were sent
out to the field site in batches where the temperature var-
ied between 23 and 31°C, humidity 50-90%.
Results of rapid diagnostic test temperature stability and in vitro QC 
testing
The CareStart™ Malaria two-line pan pLDH and Care-
Start™ Malaria three-line pan pLDH+Pf-specific pLDH
were stable to 90 days at 35°C. For the CareStart™ Malaria
three-line test, faint bands were observed on Pf (200 par-
asite/μl) samples on days 30, 60, and 90. The OptiMAL-
IT® Pf specific pLDH was stable up to day 20 at 35°C but
failed stability testing beyond this point; the pan pLDH
was stable up to day 90. All batches passed in vitro QC test-
ing.
Sensitive species PCR genotyping results
Sensitive species PCR genotyping was run on 662 enrol-
ment and follow-up specimens. These included all slide or
RDT positive samples and 20% of the negative samples
selected at random. The results for the sensitivity and spe-
cificity of microscopy and the RDTs compared to PCR are
shown in Tables 8 and 9. Table 10 provides an overall
summary of the different attributes of the tests.
Discussion
In this evaluation the OptiMAL-IT® test was the most sen-
sitive test for detection of malaria; however, this was at the
Table 3: Sensitivity, specificity, positive and negative predictive values of CareStart™ Malaria 2 line pLDH (Pan) results compared to 
microscopy results
Sensitivity Specificity Positive Predictive Value Negative Predictive Value
PF/other1
(PF gametocytaemia considered negative for PF)
89.1
[85.5-91.8]
97.6
[96.5-98.4]
93.8
[90.8-95.9]
95.2
[94.2-96.8]
PF/other2
(PF gametocytaemia considered positive for PF)
85.1
[81.3-88.2]
96.1
[94.7-97.2]
90.6
[87.3-93.2]
93.6
[91.9-95.0]
PF mono-infection1
(PF gametocytaemia considered negative for PF)
95.6
[87.7-98.5]
-- -
PF mono-infection2
(PF gametocytaemia considered positive for PF)
86.7
[79.9-91.4]
-- -
PV mono-infection1
(PV gametocytaemia considered negative for PV)
91.0
[86.5-94.1]
-- -
PV mono-infection2
(PV gametocytaemia considered positive for PV)
88.4
[83.7-91.9]
-- -
Note
1329 CareStart™ Malaria 2 line pLDH (Pan) tests performed; 13 (1%) were invalid, results were missing for 1 (0.1%) test., thus results of 1315 tests 
were evaluated.
Results expressed as % with 95% confidence intervals in brackets
Specificity not calculated for monoinfections since false positives for species individually cannot be estimated.
1 Solitary gametocytaemia considered as a negative result for that species
2Solitary gametocytaemia considered as a positive result for that speciesMalaria Journal 2009, 8:241 http://www.malariajournal.com/content/8/1/241
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expense of a slightly lower specificity than the CareStart™
Malaria tests, and hence, lower positive predictive value in
this area, particularly for the detection of falciparum
malaria or mixed falciparum/other infections.
The sensitivity of the CareStart™ Malaria pan pLDH test
for the detection of all species combined was only 85.1%
[CI95 81.3-88.2]. However breaking this down to look at
the detection of falciparum or vivax mono-infections
only, sensitivity was considerably higher at 95.6 and
91.0% respectively. This is probably explained by the
lower parasitaemia of the other infections. The CareStart™
Malaria pLDH (Pan, Pf) test was 93.5% sensitive for detec-
tion of falciparum-containing infections but performed
poorly for the detection of non-falciparum infections with
a sensitivity of only 78.5% [CI95 73-83.1] which would
limit its utility in areas with a high prevalence of non-fal-
ciparum infections.
How solitary gametocytemia was defined had a big
impact on all the results, with an important decrease in
sensitivity if a slide with Pf or Pv gametocytes, but no tro-
phozoites was counted as positive for Pf or Pv rather than
negative.
All three tests were highly sensitive for the detection of fal-
ciparum malaria monoinfections. For a parasitaemia >
100/μL all tests were >95% sensitive for the detection of
Pf meeting the criteria set out by the WHO. This is
extremely important from the point of view of patient
safety. There were five missed falciparum infections, but
these were all low parasitaemia infections, the highest
being 36 Pf trophozoites/500 white blood cells on the
thick smear.
Roll Back Malaria has only recently abandoned its recom-
mendation that children under five years of age with fever
Table 4: Sensitivity, specificity, positive and negative predictive values of CareStart™ Malaria 3 line pLDH (Pan, Pf) and OptiMAL-IT® 
results compared to microscopy
CareStart™ Malaria pLDH (Pan, PF) OptiMAL-IT®
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
Pf +/- other1 93.5
[87.8-96.7]
97.4
[96.3-98.2]
78.9
[71.6-84.7]
99.3
[98.7-99.7]
95.2
[89.8-97.9]
94.7
[93.3-95.8]
65.2
[58.0-71.8]
99.5
[98.9-99.8]
Pf +/- other2 89.1
[82.8-93.3]
98
[97-98.6]
83.7
[76.9-88.8]
98.7
[97.9-99.2]
91.8
[85.9-95.4]
95.4
[94.1-96.5]
69.5
[62.4-75.8]
99
[98.3-99.5]
Non-Pf1 78.5
[73-83.1]
97.8
[96.8-98.6]
89.5
[84.8-92.9]
95.1
[93.6-96.2]
90
[85.7-93.1]
96.5
[95.3-97.5]
85.9
[81.1-89.6]
97.6
[96.5-98.4]
Non-Pf2 77
[71.5-81.8]
97.9
[96.9-98.6]
90
[85.3-95.3]
94.6
[93.1-95.8]
90.2
[86-93.3]
97.1
[95.9-97.9]
88.2
[83.7-91.5]
97.6
[96.5-98.4]
Pf mono-
infection1
94.7
[88.9-97.5]
-- - 9 4 . 7
[88.9-97.5]
-- -
Pf mono-
infection2
90.5
[84.1-94.5]
-- - 9 2 . 1
[86-95.6]
-- -
Pv mono-
infection1
80.6
[74.9-85.3]
-- - 9 1 . 8
[87.4-94.8]
-- -
Pv mono-
infection2
78.9
[73.2-83.7]
-- - 9 2 . 1
[87.8-94.9]
-- -
Note
1337 CareStart™ Malaria 3 line pLDH (Pan, PF) tests performed; 21 (1.6%) were invalid, results were missing for 4 (0.3%) tests, thus results of 
1312 tests were evaluated.
1328 OptiMAL-IT® tests performed; 10 (0.8%) were invalid, results were missing for 1 (0.1%) test, thus results of 1317 tests were evaluated.
Results expressed as % with 95% confidence intervals in brackets
Specificity not calculated since false positives for species individually cannot be estimated.
1 Solitary gametocytaemia considered as a negative result for that species
2Solitary gametocytaemia considered as a positive result for that speciesMalaria Journal 2009, 8:241 http://www.malariajournal.com/content/8/1/241
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in high transmission areas should be treated for malaria
rather than performing a diagnostic test. There was no
indication that the tests performed differently in younger
age groups; however numbers of young children included
were small.
The CareStart™ Malaria tests became negative rapidly at a
median time of two days, a big advantage if deployed for
diagnosis in high transmission areas, where reinfection is
common. The OptiMAL-IT® test took a longer time to
become negative (seven days) although this is still faster
than HRP-2 based tests.
Stability testing of the CareStart™ Malaria tests was satis-
factory, but the OptiMAL-IT® batch used in the study failed
to demonstrate stability of the Pf pLDH band beyond 20
days at 35°C, which is poor, especially considering that
these tests are used in tropical countries where tempera-
tures above 35°C are common. Inter-observer agreement
between readers was high for all tests but the result was
not stable after a week (Table 7), thus in practice tests can-
not be stored to review the results at a later date. With
training the tests were easy to use but the number of steps
to perform the OptiMAL-IT®  test meant it was fairly
labour-intensive and not necessarily an ideal test for a
crowded waiting room in a health post. The instructions
provided with the CareStart™ Malaria three line pLDH
(pan, Pf) test were a little confusing. They state that a test
with a positive control line, positive Pf pLDH band and
negative pLDH (Pan) should be interpreted as Pf. For
OptiMAL-IT® both Pf and pan pLDH bands must be posi-
tive to interpret the test as Pf. On contacting the manufac-
turers they explained that this is because the pLDH is
sometimes completely used up by the Pf pLDH band.
It is usually assumed that PCR is more sensitive and spe-
cific for diagnosis than microscopy. Expert microscopy vs
PCR would be expected to have specificity close to 100%
Table 5: Sensitivity of RDTs at a parasitaemia above and below 100/μL
Microscopy result
N PF <100/μL
21
PF ≥ 100/μL
92
PV <100/μL
35
PV≥ 100/μL
183
CareStart™ Malaria pLDH (Pan) 76.2
[54.9-89.4]
100
[96-100]
45.7
[30.5-61.8]
99.5
[97.0-99.9]
CareStart™ Malaria pLDH (Pan, PF) 76.2
[54.9-89.4]
98.9
[94.1-99.8]
25.7
[14.2-42.1]
90.7
[85.6-94.1]
OptiMAL-IT® 81
[60-92.3]
97.8
[92.4-99.4]
62.9
[46.3-76.8]
97.3
[93.7-98.8]
95%CIs for the difference
C2 PF: 0.1-0.45; PV:0.375-0.690
C3 PF: 0.087-0.440; PV:0.479-0.770
OTM: PF: 0.043-0.379; PV: 0.20-0.51
Table 6: Sensitivity, % [CI95] of the RDTs in the above and below 5 year age groups for the diagnosis of single-species infections 
compared to microscopy
NP F
Age < 5 y
12
PF
Age ≥ 5 y
101
PV
Age < 5 y
51
PV
Age ≥ 5 y
170
CareStart™ Malaria 2 line pLDH (Pan) 100
[75.7-100]
95
[88.9-97.9]
88.2
[76.6-94.5]
91.8
[86.7-95.0]
CareStart™ Malaria 3 line pLDH (Pan, PF) 91.7
[64.6-98.5]
95.0
[88.9-97.9]
80.4
[67.5-89.0]
80.6
[74.0-85.8]
OptiMAL-IT® 91.7
[64.6-98.5]
95.0
[88.9-97.9]
92.2
[81.5-96.9]
91.7
[86.6-95.0]
95% CIs for the difference:
C2 PF: -0.112 to 0.194; PV: -0.046 to 0.156
C3: PF: -0.306 to 0.058; PV: -0.141 to 0.106
OTM: PF: -0.306 to 0.058; PV: -0.107 to 0.074Malaria Journal 2009, 8:241 http://www.malariajournal.com/content/8/1/241
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[17]. In this study, specificity for detection of Pv was lower
than for Pf. Possible explanations are inaccurate micros-
copy (despite the QA/QC measures in place), sub-optimal
sensitivity of the PCR method or probably a combination
of the two. The advantage of using expert microscopy over
PCR sensitive species genotyping is that it gives informa-
tion about parasite stage and parasitaemia. PCR may be a
good alternative in areas where expert microscopy cannot
be put in place for a study or in travellers returning to non-
endemic areas. In an endemic area PCR may detect an
infection that has cleared below the limit if microscopic
detection or has been treated. Surprisingly, only three sub-
jects (0.3%) admitted to having taken antimalarials
before presenting to the clinic.
A large number of patients presenting with fever or history
of fever (64.7%) did not have malaria. This low preva-
lence was reflected in the relatively low PPV of the Opti-
MAL-IT® test of 69.5% [95%CI 62.4-75.8] for falciparum-
containing infections. Malaria is not the only disease for
which improved diagnostics are needed at field level.
Leptospirosis and rickettsial diseases, such as scrub and
murine typhus, are common in SE Asia. Describing the
epidemiology of fever in this population would lead to
improved case management. Among those who did have
malaria, the vivax prevalence was more than double that
of falciparum, a reversal of the ratio observed in 2006 in
the same area. The explanation for this is unclear since
ACT has been available to treat falciparum malaria in this
area for some years. However, access may have improved
in adjacent areas as a large donation of artemether-lume-
fantrine was deployed in government clinics across Myan-
mar in 2007 with a consequent impact on transmission of
falciparum malaria.
The OptiMAL-IT® was highly sensitive for the detection of
falciparum and vivax malaria and would perform best in
an area of high malaria prevalence among screened fever
cases. However heat stability was not acceptable and the
number of steps to perform this test is a significant draw-
back in the field.
The CareStart™ Malaria pLDH (Pan) test may be a good
alternative to Paracheck-Pf™ in areas where the predomi-
nant species is P. falciparum, particularly if transmission is
high since it becomes negative rapidly.
Heat stability remains a major concern for the pLDH tests
and stability testing at intervals as part of quality assur-
ance and quality control of malaria diagnostic procedures
Table 7: Inter-observer agreement for the 3 rapid diagnostic tests
1st and 2nd reading 1st and 3rd reading
N kappa N kappa
CareStart™ Malaria 2 line pLDH (Pan) 1315 0.967 1295 0.341
CareStart™ Malaria 3 line pLDH (Pan, PF) 1312 0.941 1258 0.280
OptiMAL-IT® 1316 0.923 1296 0.341
A kappa value of > 0.8 signifies very good agreement
2nd reading performed 10 minutes after the 1st; 3rd reading performed 1 week after the 1st.
Table 8: Sensitivity and specificity of microscopy and CareStart™ Malaria 2 line pLDH (Pan) compared to sensitive species PCR 
genotyping
Microscopy CareStart™ Malaria 2 line pLDH (Pan)
Sensitivity Specificity
Overall 91.6
[88.3-94.0]
90.0
[85.7-93.1]
87.7
[84.1-90.6]
87.0
[82.4-90.6]
PF monoinfection 91.1
[84.8-95.0]
97.9
[96.2-98.8]
90.8
[84.6-94.6]
-
PV monoinfection 90.8
[86.3-94.0]
93.9
[91.2-95.8]
90.4
[85.7-93.6]
-
Note
PFG/PVG counted as a positive microscopy result for the purposes of this analysis
MP counted as negativeMalaria Journal 2009, 8:241 http://www.malariajournal.com/content/8/1/241
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is recommended in programmes using pLDH based RDTs.
Unless manufacturers provide convincing data on heat
stability from different test batches, a rapid diagnostic test
should not be recommended.
Choosing a rapid diagnostic test to deploy in the field
depends on numerous factors. High sensitivity and specif-
icity for detection of disease are the most important fea-
tures of a good test; however these become less relevant if
the test is not heat-stable in field conditions, if the test is
too complicated to perform or if inter-observer agreement
is poor. Cost is also a factor, but costs may vary greatly
depending on the quantity ordered and a recent increase
in the number of tests on the market should lead to prices
coming down.
The drawbacks of the HRP-2 tests have been described;
however it could be argued that these are outweighed by
their high sensitivity for detection of potentially life-
threatening falciparum malaria and their superior heat
stability.
The approach used here to select tests at random and eval-
uate them is expensive and labour intensive. The results of
the first round of the WHO product testing have been
published recently. In general, highest Pf detection rates
were demonstrated by tests targeting HRP2. Batch-to-
batch variation was also observed leading to the recom-
mendation to test new lots post purchase and prior to use
[18]. This initiative by the WHO to centralize RDT evalu-
ations and perform in vitro QC and stability testing is wel-
Table 9: Sensitivity and specificity of CareStart™ Malaria 3 line pLDH (Pan, PF) and OptiMAL-IT® compared to sensitive species PCR 
genotyping
CareStart™ Malaria three line pLDH (Pan, PF) OptiMAL-IT® pLDH (Pan, PF)
Sensitivity Specificity Sensitivity Specificity
PF +/- other 86.0
[79.5-90.7]
95.9
[93.8-97.3]
92.6
[87.2-95.8]
91.4
[88.7-93.5]
Non-PF 77.3
[71.7-82.0]
93.6
[90.8-95.6]
89.2
[84.7-92.5]
90.2
[86.9-92.8]
PF monoinfection 78.6
[71.1-84.6]
-9 1 . 5
[85.5-95.2]
-
PV monoinfection 78.4
[72.5-83.4]
-9 0 . 3
[85.7-93.6]
-
Table 10: Summary table of test performance
CareStart™ Malaria 2 line pLDH 
(Pan)
CareStart™ Malaria three line pLDH 
(Pan, PF)
OptiMAL-IT®
PF detection1 sensitivity % [CI95] 95.6
[87.7-98.5]
94.7
[88.9-97.5]
94.7
[88.9697.5]
PV detection1 sensitivity % [CI95] 91
[86.5-94.1]
80.6
[74.9-85.3]
91.8
[87.4-94.8]
Heat stable at 90 days at 35°C Yes Yes No
Ease of Use Ranking 11 3
Time to negative, days 2 2 7
Inter-reader agreement Excellent Excellent Excellent
Cost (USD) 0.6 1 1.5
Invalid tests % 1 1.6 0.8
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comed as this should accelerate the process of getting
much needed reliable rapid diagnostic tests in the field.
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